IO Biotech Inc [IOBT] stock prices are down -0.06% to $0.48 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The IOBT shares have gain 31.94% over the last week, with a monthly amount drifted -75.30%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
IO Biotech Inc [NASDAQ: IOBT] stock has seen the most recent analyst activity on September 30, 2025, when TD Cowen downgraded its rating to a Hold. Previously, Morgan Stanley downgraded its rating to Equal-Weight on September 30, 2025, and kept the price target unchanged to $0.39.
The stock price of IO Biotech Inc [IOBT] has been fluctuating between $0.32 and $2.79 over the past year. IO Biotech Inc [NASDAQ: IOBT] shares were valued at $0.48 at the most recent close of the market.
Analyzing the IOBT fundamentals
Gross Profit Margin for this corporation currently stands at -0.28% with Operating Profit Margin at -116.71%, Pretax Profit Margin comes in at -121.26%, and Net Profit Margin reading is -122.34%. To continue investigating profitability, this company’s Return on Assets is posted at -2.46, Equity is -2.82 and Total Capital is -4.42. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 5.25.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.4580 points at the first support level, and at 0.4342 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.5275, and for the 2nd resistance point, it is at 0.5732.
Ratios To Look Out For
It’s worth pointing out that IO Biotech Inc [NASDAQ:IOBT]’s Current Ratio is 1.96. Also, the Quick Ratio is 1.96, while the Cash Ratio stands at 1.41.
Transactions by insiders
Recent insider trading involved Hunter Heidi, Director, that happened on May 30 ’25 when 15000.0 shares were purchased. Chief Medical Officer, Ahmad Qasim Iftikhar completed a deal on Dec 23 ’24 to buy 31350.0 shares. Meanwhile, Chief Executive Officer Zocca Mai-Britt bought 12500.0 shares on Dec 23 ’24.
